Skip to content

FDA accepts Athenex application for oral paclitaxel for breast cancer

September 1, 2020

Under Priority Review status, the FDA has accepted Athenex’s (NASDAQ:ATNX) marketing application seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast cancer.

The agency’s action date is February 28, 2021.

https://seekingalpha.com/news/3610363-fda-accepts-athenex-application-for-oral-paclitaxel-for-breast-cancer

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: